IMRIS sells IMRISneuro to Le Bonheur Children's Medical Center

IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced the sale of its flagship product, IMRISneuro, to Le Bonheur Children's Medical Center. Neurosurgeons from the collaborative brain tumor program at Le Bonheur and St. Jude Children's Research Hospital, the largest research-based pediatric brain tumor program in the United States, will use this leading-edge technology to perform life-saving brain tumor surgery. Currently under construction, the Le Bonheur state-of-the-art neurosurgical facility, partially funded by a donation from St. Jude to further both organizations' charitable missions, will house the IMRISneuro system when the facility opens in 2010. This will be the first 3T intra-operative MR for pediatric neurosurgery in North America.

IMRISneuro provides timely, high resolution MR images to the medical team before, during and after an operation without moving the patient from the surgical table. The wide bore 3T MRI will move between an operating theatre and a diagnostic facility, providing state-of-the-art, multi-functional capabilities to the hospital's neuroscience facility. No other system offers the same degree of safety for both the patient and the surgical environment. IMRISneuro does not require the patient to be transported for scanning, so the optimum position for neurosurgery is never compromised. Clinical workflow and surgical access to the patient is not impacted and the magnet is removed completely from the operating room when scanning is complete. The IMRISneuro system provides neurosurgeons with timely images during surgery from which they are able to make better decisions for their patients.